SCHEMBL3773197

SCHEMBL3773197

Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.66
MEN1 O00255 2/20 0.66
TDP1 Q9NUW8 1/20 0.66
KDM4E B2RXH2 2/20 0.56
POLB P06746 1/20 0.56
GAA P10253 1/20 0.53
ATM Q13315 1/20 0.53
TSHR P16473 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
USP2 O75604 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
GHSR Q92847 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799209 0.84 NPC1 (0.52) KMT2AMEN1KDM4EPOLBTSHR
SCHEMBL3773336 0.80 MGLL (0.52) KMT2AKDM4EALDH1A1LMNAL3MBTL1
SCHEMBL3763003 0.79 CCR5 (0.58) KMT2AMEN1KDM4EPOLBNPSR1
SCHEMBL3770185 0.76 HRH3 (0.47) KDM4EGAAALDH1A1L3MBTL1
SCHEMBL3773907 0.76 KDM2B (0.53) KMT2AMEN1KDM4EPOLBGAA
SCHEMBL4977928 0.76 KDM4E (0.58) KMT2AMEN1TDP1KDM4EPOLB
SCHEMBL3765235 0.76 HRH3 (0.51) KDM4EALDH1A1L3MBTL1
SCHEMBL3545942 0.76 KMT2A (0.78) KMT2AKDM4EPOLBGAATSHR
SCHEMBL3761223 0.75 ALDH1A1 (0.53) KMT2AMEN1KDM4EPOLBCYP2C9
SCHEMBL3768053 0.75 KMT2A (0.57) KMT2AMEN1KDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885MEN1 3270/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.